-+ 0.00%
-+ 0.00%
-+ 0.00%

Regenxbio to host investor event on sura-vec wet AMD program ahead of pivotal data readout

PUBT·10/12/2026 11:05:24
Listen to the news
Regenxbio to host investor event on sura-vec wet AMD program ahead of pivotal data readout
  • Regenxbio will host an investor event on Oct. 20, 2026 at 1:00 p.m. ET in New York, with a webcast option.
  • The session will highlight surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet age-related macular degeneration ahead of pivotal topline data expected in 4Q 2026.
  • Management plans to review the wet AMD program, including the ATMOSPHERE and ASCENT pivotal trials, with outside retina specialists.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610120705PR_NEWS_USPR_____PH69543) on October 12, 2026, and is solely responsible for the information contained therein.